Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 13Withdrawn 3Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Classical hematology 1

Conditions

Neoplasms 1Fatigue 1Anemia 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Epoetin Alfa × Clear all
NCT00624312 2021-08-06

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

University of Louisville

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00052221 2018-11-08

Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy

M.D. Anderson Cancer Center

Phase NA Withdrawn

Fatigue

NCT00481624 2018-03-05

Procrit

University of Louisville

Phase 2 Withdrawn
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡